# Study to Evaluate Markers of Response in Locally Advanced Breast Cancer

> **NCT01338753** · PHASE2 · COMPLETED · sponsor: **Clinica Universidad de Navarra, Universidad de Navarra** · enrollment: 74 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **OTHER:** Bevacizumab, docetaxel and doxorubicin followed by surgery

## Key facts

- **NCT ID:** NCT01338753
- **Lead sponsor:** Clinica Universidad de Navarra, Universidad de Navarra
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-10
- **Final completion:** 2011-05
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2013-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01338753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01338753, "Study to Evaluate Markers of Response in Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01338753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*